Kiora publishes results from Phase 1 study demonstrating safety, tolerability and efficacy of KIO-101
Ophthalmology Times Europe,
KIO-101 is the designation for topical delivery and KIO-104 is the designation for intravitreal injection.
Kiora publishes results from study demonstrating safety, tolerability and efficacy of KIO-101 for treatment of inflammation of the eye
Ophthalmology Times,
(Image Credit: AdobeStock/Davizro Photography) Kiora Pharmaceuticals Inc announced the publication of results from a Phase 1…
Kiora Pharmaceuticals reports positive results for eye inflammation drug
Investing.com - UK,
KPRX -4.84% Add to/Remove from a Portfolio Add to Watchlist Add Position Position added successfully to: + Add another position…
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
Crwe World,
Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc.